Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2000
12/28/2000CA2373921A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
12/28/2000CA2373497A1 Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
12/27/2000EP1063298A2 Transgenic Animal Model for Alzheimer Disease
12/27/2000EP1063228A1 Cycloalkene derivatives, process for producing the same, and use
12/27/2000EP1062517A2 Diagnosis of spongiform encephalopathies using prionins
12/27/2000EP1062339A2 Human fgf gene and gene expression products
12/27/2000EP1062334A1 Mammalian sodium channel proteins
12/27/2000EP1062323A2 Methods of diagnosis and triage using cell activation measures
12/27/2000EP1062236A1 31 human secreted proteins
12/27/2000EP1062229A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
12/27/2000EP1062226A1 High affinity nucleic acid ligands of complement system proteins
12/27/2000EP1062222A1 Serine peptidase modulators
12/27/2000EP1062218A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
12/27/2000EP1062212A1 Heterocyclyl anthracyclinone derivatives
12/27/2000EP1062210A1 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
12/27/2000EP1062206A2 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis
12/27/2000EP1062204A1 Modulators of protein tyrosine phosphatases (ptpases)
12/27/2000EP1062199A1 Modulators of protein tyrosine phosphatases (ptpases)
12/27/2000EP1061952A2 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
12/27/2000EP1061944A2 Therapeutic chemokine receptor antagonists
12/27/2000EP1061943A1 Method of preventing the death of retinal neurons and treating ocular diseases
12/27/2000EP1061940A2 Use of follistatin to modulate gdf-8 and bmp-11
12/27/2000EP1061936A1 Cyclic dipeptides and azetidinone compounds and their use in treating cns injury and neurodegenerative disorders
12/27/2000EP1061926A2 Heterocyclic compounds, their production and use as tachykinin receptor antagonists
12/27/2000EP1061925A1 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist
12/27/2000EP1061923A2 Metal chelators for use in the treatment of alzheimer's disease
12/27/2000EP1061919A1 Novel opiate compounds, methods of making and methods of use
12/27/2000EP1061918A1 Controlled release composition of (1-azabicyclo(2.2.2)oct-3-yl)acetonitrile monohydrochloride
12/27/2000EP1061901A1 Nicotine inhaler
12/27/2000EP1061887A1 Novel use of phospholipids of vegetable and animal origin in nutritional therapy
12/27/2000EP1061805A1 Regulation of endogenous gene expression in cells using zinc finger proteins
12/27/2000EP0891322B1 Dimethyl-substituted cyclohexane diene derivatives
12/27/2000EP0821666B1 Derivatives of succinamide and their use as metalloproteinase inhibitors
12/27/2000CN1278269A Piperazine-cyclodextrin complexes
12/27/2000CN1278263A 2,3-diaryl-pyrazolo [1,5-B] pyridazines derivatives, their prepn. and use as cyclooxygenase 2 (cox-2) inhibitors
12/27/2000CN1278260A Aminomethyl-benzo [a] quinolizidine derivatives, prepns. and therapeutic applications for neurodegenrative diseases
12/27/2000CN1278258A Azaring-ether derivatives and their use as nicotinic ach receptor modulators
12/27/2000CN1278249A Biphenyl derivatives as pharmaceuticals
12/27/2000CN1278174A Nicotine compositions and method for formulation thereof
12/27/2000CN1278165A Extended release formulation contg. venlafaxin
12/27/2000CN1278158A Synergistic analgestic combination of opioid analgsic and cyclooxygenase-2
12/27/2000CN1277962A Novel substituted dipolymer compounds, prepn. method therefor, pharmaceutical compositions contg. same
12/27/2000CN1277863A Pharmaceutical for treating injury type vetebral injure
12/27/2000CN1277852A Pharmaceutical for preventing and treating senile dementia and depression, and its prepn. process
12/26/2000US6166216 Compounds useful as neuro-protective agents
12/26/2000US6166209 Piperidine derivatives
12/26/2000US6166206 Pyrrolo[3,4-D]Pyrimidinone derivatives and their use as medicaments
12/26/2000US6166193 Nucleotide sequence which encodes g-protein coupled receptor; for the treatment and prevention of bacterial, fungal, protozoan and viral infections; for use in gene therapy
12/26/2000US6166182 Polypeptides for the treatment of bacterial, fungal, protozoan and viral infections
12/26/2000US6166087 Immunosuppresants, antiinflammatory agents, antitumor agents;applying to mucous membranes
12/26/2000US6166085 Administering 2-(ethylamino)-n-(3-hydroxy-2,6-dimethylphenyl) acetamide
12/26/2000US6166077 Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1
12/26/2000US6166064 Antiinflammatory agents; antiarthritic agents
12/26/2000US6166060 Antihistamines; sleep disorders; central nervous system disorders
12/26/2000US6166055 Antiinflammatory agents
12/26/2000US6166040 Treating a disorder of the central nervous system
12/26/2000US6166039 Peripherally active anti-hyperalgesic opiates
12/26/2000US6166034 Spiro piperidine derivatives as 5HT1D receptor antagonists
12/26/2000US6166030 An inhibitors of the neuronal isoform of nitric oxide synthase; treating hypoxia, stroke, ischaemia, neurodegenerative conditions, schizophrenia, pain, migraine
12/26/2000US6166027 Treatment of high blood pressure and cardiac insufficiency, angina pectoris, arrhythmias, thromboembolic diseases, ischaemias, myocardial infarction, cerebral stroke, restenoses, coronary angioplasties, arteriosclerosis
12/26/2000US6166025 A stable, aqueous drug formulation for treating migraine
12/26/2000US6166020 Aryl and heteroaryl alkoxynaphthalene derivatives
12/26/2000US6166011 For treatment of disorders arising from neurodegenerative diseases or other disorders involving nerve damage
12/26/2000US6166008 Treatment of schizophrenia with ampakines and neuroleptics
12/26/2000US6165766 Amino acid sequence of serine/threonine protein kinase; anticarcinogenic/antiarthritic/antiinflammatory agents; treatment of osteoporosis, adult respiratory disease syndrome, inflammatory bowel disease, eating disorders; diagnosis
12/26/2000US6165763 Nucleotide and amino acid sequences of enzyme from streptococcus; for drug screening of bacteriostats and bactericides
12/26/2000US6165759 Amino acid sequence; diagnosis, prophylaxis and therapy of infections; vaccines; bacteriostats; bactericides; screening of enzyme inhibitors and activators
12/26/2000US6165752 Expression system which produces polypeptide of defined amino acid sequence when present in a cell; diagnosis and therapy for creutzfeldt-jakob disease and nervous system disorders; anticarcinogenic agents
12/26/2000US6165751 HLDAT86 polynucleotides
12/26/2000US6165732 Drug screening by using lipid bilayer that has potassium- or chloride-selective channel formed from polpeptide of bcl-2 family, contacting compound with bilayer, and determining ion-selectivity of channel; indicates agonist or antagonist
12/26/2000US6165506 A solid dose nanoparticulate naproxen formulation having a high rate of dissolution comprising a naproxen having specific particle size, polyvinylpyrrolidone adsorbed on the surface and an alkali agent to increase the dissolution rate
12/25/2000CA2475401A1 Method for the preparation of citalopram
12/22/2000CA2291542A1 Novel composition
12/21/2000WO2000077256A1 48 human secreted proteins
12/21/2000WO2000077255A1 49 human secreted proteins
12/21/2000WO2000077237A1 49 human secreted proteins
12/21/2000WO2000077233A2 Complement-resistant non-mammalian dna viruses and uses thereof
12/21/2000WO2000077226A1 22025, a novel human cyclic nucleotide phosphodiesterase
12/21/2000WO2000077206A2 The myostatin gene promoter and inhibition of activation thereof
12/21/2000WO2000077199A1 Cloning and expression of a novel 5-ht4 receptor
12/21/2000WO2000077184A1 Caspase-8 crystals, models and methods
12/21/2000WO2000077179A2 Human poly(adp-ribose) polymerase 2 materials and methods
12/21/2000WO2000077178A1 IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
12/21/2000WO2000077173A1 42 human secreted proteins
12/21/2000WO2000077168A2 ANTAGONISTS OF BMP AND TGFβ SIGNALLING PATHWAYS
12/21/2000WO2000077045A1 Novel protein and dna thereof
12/21/2000WO2000077040A2 Human intracellular signaling molecules
12/21/2000WO2000077035A2 Novel potassium channels and genes encoding these potassium channels
12/21/2000WO2000077033A1 Retro-inverso peptides derived from interleukin-6
12/21/2000WO2000077030A1 Statine-derived tetrapeptide inhibitors of beta-secretase
12/21/2000WO2000077029A1 Retro-inverso peptides derived from leukemia inhibitory factor
12/21/2000WO2000077028A1 Retro-inverso peptides derived from interleukin-3
12/21/2000WO2000077023A1 48 human secreted proteins
12/21/2000WO2000077022A1 50 human secreted proteins
12/21/2000WO2000077018A2 Purine derivatives
12/21/2000WO2000077010A2 Substituted heterocycle fused gamma-carbolines
12/21/2000WO2000077004A1 1-azatricyclic-4-benzylpiperazines
12/21/2000WO2000077002A1 Substituted heterocycle fused gamma-carbolines
12/21/2000WO2000077001A1 Substituted heterocycle fused gamma-carbolines
12/21/2000WO2000076990A1 New compounds
1 ... 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 ... 1833